Once-monthly risedronate for postmenopausal osteoporosis
نویسندگان
چکیده
Bisphosphonates are the mainstay of treatment for postmenopausal women with osteoporosis. Despite numerous clinical trials documenting efficacy, tolerability, and safety of bisphosphonate therapy, long-term persistence and adherence to these agents remains low. This has serious consequences for patients with osteoporosis in that medication non-compliance is associated with significantly higher fracture risk. This review explores the unique physicochemical properties of bisphosphonates that allow more convenient intermittent dosing and whether less frequent dosing regimens improve compliance. Bisphosphonates are now available as oral drugs (taken daily, weekly, or monthly) or as intravenous preparations (given every 3 months or annually). The safety and efficacy of these various preparations are reviewed and compared, with particular emphasis on the newest agent to be approved, once-monthly risedronate. In contrast to monthly oral ibandronate, risedronate is the first and only monthly oral bisphosphonate to offer both vertebral and non-vertebral fracture reduction, based upon non-inferiority trials. Whether the greater convenience of this monthly oral bisphosphonate will translate into improved compliance and lower fracture risk is yet to be determined.
منابع مشابه
Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis
Postmenopausal osteoporosis increases susceptibility to low-trauma fractures due to reduced bone volume and microarchitectural deterioration. Daily nitrogen-containing bisphosphonates have shown antifracture efficacy in many studies and are the most commonly prescribed treatment for women with postmenopausal osteoporosis. However, optimal efficacy is often not achieved due to poor patient adher...
متن کاملMonthly Risedronate for the Treatment of Postmenopausal Osteoporosis
Osteoporosis mostly affects postmenopausal women and substantially increases their risk of fracture. Fractures associated with osteoporosis (fragility fractures) have a major impact on quality of life, mortality, and health care costs. Therefore, it is important to prevent fragility fractures in patients with postmenopausal osteoporosis. The ideal osteoporosis treatment is a drug therapy with t...
متن کاملOptimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations
Postmenopausal osteoporosis is common and underrecognized among elderly women. Osteoporotic fractures cause disability and disfigurement and threaten patients' mobility, independence, and survival. Care for incident fractures in this age group must go beyond orthopedic repair, to assessment and treatment of the underlying bone fragility. Fracture risk can be reduced by vitamin D and calcium sup...
متن کاملPersistence with weekly and monthly bisphosphonates among postmenopausal women: analysis of a US pharmacy claims administrative database
BACKGROUND Bisphosphonates are available in daily, weekly, and monthly dosing formulations to treat postmenopausal osteoporosis. Some researchers suggested that adherence to monthly bisphosphonate might be different from that with weekly or daily bisphosphonate because of different dosing regimens. However, the actual persistency rates in regular practice settings are unknown. OBJECTIVES To c...
متن کاملEfficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis
Fragility fractures that occur as a result of osteoporosis are frequently associated with chronic pain and decreased quality of life as well as significant morbidity and mortality. Fracture reduction, however, is often less than optimal due to poor compliance with medications. Studies have demonstrated that risedronate, a heterocyclic nitrogen containing bisphosphonate can reduce vertebral, non...
متن کامل